Pharmacokinetics and metabolism of UK-383,367 in rats and dogs: A rationale for long-lived plasma radioactivity

References

• Boll M, Foltz M, Rubio-Aliaga I, Kottra G, Daniel H. Functional characterisation of two novel mammalian electrogenic proton-dependent amino acid cotransporters. Journal of Biological Chemistry 2002; 277: 22966–22973
   PubMed Web of Science ®Google Scholar
• Bröer A, Klingel K, Kowalczuk S, Rasko J, Cavanaugh J, Bröer S. Molecular cloning of mouse amino acid transport system B0, a neutral amino acid transporter related to Hartnup Disorder. Journal of Biological Chemistry 2004; 279: 24467–24476
   PubMed Web of Science ®Google Scholar
• Choi MH, Jung BH, Chung BC. Identification of urinary metabolites of clemastine after oral administration to man. Journal of Pharmacy and Pharmacology 1999; 51: 53–59
   PubMedGoogle Scholar
• Fishbein WN, Streeter CL, Daly J. Physiologic disposition of short chain aliphatic hydroxamates in the mouse. II. Absorption, distribution, metabolism and excretion of 1-14C-acetohydroxamic acid. Journal of Pharmacology and Experimental Therapeutics 1973; 186(1)173–182
   PubMedGoogle Scholar
• Gardner IB, Walker DK, Lennard MS, Smith DA, Tucker GT. Comparison of the disposition of two novel combined thromobxane synthase inhibitors/thromboxane A2 receptor antagonists in the isolated perfused rat liver. Xenobiotica 1995; 25: 185–197
   PubMed Web of Science ®Google Scholar
• Gomes P, Soares-da-Silva P. Na+-indepenedent transporters, LAT-2 and b0,+, exchange L-DOPA with neutral and basic amino acids in two clonal renal cell lines. Journal Membrane Biology 2002; 186: 63–80
   PubMed Web of Science ®Google Scholar
• Gyarmati L, Csontos A, Racz I, Satori EVA, Harsanyi K. Zum metabolismus des 3-[4-pyridyl]-5- [2-chlorphenyl]-1,2,4-oxdiazols in der ratte. Pharmazie 1976; 31: 246–247
   PubMedGoogle Scholar
• Honohan T, Fitzpatrick FA, Booth DG, McGrath JP, Morton DR, Nishizawa EE. Hydrolysis of an orally active platelet inhibitory prostanoid amide in the plasma of several species. Prostaglandins 1980; 19: 123–138
   PubMedGoogle Scholar
• Kalgutkar AS, Gardner I, Obach RS, Shaffer CL, Callegari E, Henne KR, Mutlib AE, Dalvie DK, Lee JS, Nakai Y, O’Donnell JP, Boer J, Harriman SP. A comprehensive listing of bioactivation pathways of organic functional groups. Current Drug Metabolism 2005; 6: 161–225
   PubMed Web of Science ®Google Scholar
• Lan SJ, Weliky I, Schreiber EC. Metabolic studies with trans-5-amino-3-{2-(5-nitro-2-furyl) vinyl}-1,2,4,[5-14C] oxadiazole (SQ 18,506): 1. Reductive cleavage of the 1,2,4-oxadiazole ring. Xenobiotica 1973; 3: 97–102
   PubMed Web of Science ®Google Scholar
• Manchee GR, Eddershaw PJ, Ranshaw LE, Herriott D, Park GR, Bayliss MK, Tarbit MH. The aliphatic oxidation of salmeterol to α-hydroxysalmeterol in human liver microsomes is catalysed by CYP3A. Drug Metabolism and Disposition 1996; 24: 555–559
   PubMed Web of Science ®Google Scholar
• Manderville RA. A case for the genotoxicity of ochratoxin A by bioactivation and covalent DNA adduction. Chemical Research in Toxicology 2005; 18: 1091–1097
   PubMed Web of Science ®Google Scholar
• Nakai Y, Kanai Y, Tanayama S. Metabolic disposition of 3-[4-(1-ethoxycarbonyl-1-methyl-ethoxy)phenyl]-5-(3-pyridyl)-1,2,4,-oxadiazole (AT-308), a hypocholesterolemic agent in rats. Journal of the Takeda Research Laboratory 1977; 36: 46–52
   Google Scholar
• Obach RS. Potent inhibition of human liver aldehyde oxidase by raloxifene. Drug Metabolism and Disposition 2004; 32: 89–97
   PubMed Web of Science ®Google Scholar
• Palacín M, Nunes V, Font-Llitjós M, Jiménez-Vidal M, Fort J, Gasol E, Pineda M, Feliubadaló L, Chillarón J, Zorzano A. The genetics of heteromeric amino acid transporters. Physiology 2005; 20: 112–124
   PubMed Web of Science ®Google Scholar
• Prockop DJ, Kivirikko KI. Collagens: Molecular biology, diseases, and potentials for therapy. Annual Review of Biochemistry 1995; 64: 403–434
   PubMed Web of Science ®Google Scholar
• Robinson LA, Wilson DM, Delaet NGJ, Bradley EK, Dankwardt SM, Campbell JA, Martin RL, Martin HE, Van HE, Walker KAM, Sullivan RW. Novel inhibitors of procollagen C-proteinase. Part 2: Glutamic acid hydroxamates. Bioorganic and Medicinal Chemistry Letters 2003; 13: 2381–2384
   PubMed Web of Science ®Google Scholar
• Sanderson L, Taylor GW, Aboagye EO, Alao JP, Latigo JR, Coombes RC, Vigushin DM. Plasma pharmacokinetics and metabolism of the histone deacetylase inhibitor trichostatin A after intraperitoneal administration to mice. Drug Metabolism and Disposition 2004; 32: 1132–1138
   PubMed Web of Science ®Google Scholar
• Sassard J, Pozet N, McAinsh J, Legheand J, Zech P. Pharmacokinetics of atenolol in patients with renal impairment. European Journal of Clinical Pharmacology 1977; 12: 175–180
   PubMedGoogle Scholar
• Strolin Benedetti M, Coupez R, Whomsley R, Nicolas JM, Collart P, Baltes E. Comparative pharmacokinetics and metabolism of levetiracetam, a new anti-epileptic agent, in mouse, rat, rabbit and dog. Xenobiotica 2004; 34: 281–300
   PubMed Web of Science ®Google Scholar
• Sundberg C, Ivarsson M, Gerdin B, Rubin K. Pericytes as collagen-producing cells in excessive dermal scarring. Laboratory Investigation 1996; 74: 452–466
   PubMedGoogle Scholar
• Tang-Liu DD, Tozer TN, Riegelman S. Urine flow-dependence of theophylline renal clearance in man. Journal of Pharmacokinetics and Biopharmaceutics 1982; 10: 351–364
   PubMedGoogle Scholar
• Verrey F, Ristic Z, Romeo E, Ramadan T, Makrides V, Dave MH, Wagner CA, Camargo SMR. Novel renal amino acid transporters. Annual Review of Physiology 2005; 67: 557–572
   PubMedGoogle Scholar
• Yabuki M, Shono F, Nakatsuka I, Yoshitake A. Novel cleavage of the 1,2,4-oxadiazole ring in rat metabolism of SM-6586, a dihydropyridine calcium antagonist. Drug Metabolism and Disposition 1993; 21: 1167–1169
   PubMedGoogle Scholar
• Yang L, Liu L, Olsen BA, Nussbaum MA. The determination of oxalic acid, oxamic acid and oxamide in a drug substance by ion-exclusion chromatography. Journal of Pharmaceutical and Biomedical Analysis 2000; 22: 487–493
   PubMed Web of Science ®Google Scholar
• Zhang D, Krishna R, Wang L, Zeng J, Mitroka J, Dai R, Narasimhan N, Reeves RA, Srinivas NR, Klunk LJ. Metabolism, pharmacokinetics, and protein covalent binding of radiolabelled Maxipost (BMS-204352) in humans. Drug Metabolism and Disposition 2005; 33: 83–93
   PubMed Web of Science ®Google Scholar